Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shares traded up 4.3% during trading on Tuesday . The company traded as high as $4.63 and last traded at $4.61, with a volume of 657,598 shares changing hands. The stock had previously closed at $4.42.

A number of research analysts have recently commented on the company. Zacks Investment Research downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Cowen and Company reiterated a “neutral” rating on shares of Keryx Biopharmaceuticals in a report on Wednesday, August 3rd. Raymond James Financial Inc. increased their price objective on Keryx Biopharmaceuticals from $7.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, August 2nd. Ladenburg Thalmann increased their price objective on Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Finally, Brean Capital downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $7.75.

The company’s market capitalization is $496.65 million. The firm has a 50 day moving average price of $5.89 and a 200-day moving average price of $5.31.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.14. During the same quarter last year, the business posted ($0.26) EPS. The company earned $9.30 million during the quarter, compared to analyst estimates of $8.60 million. The business’s quarterly revenue was up 272.0% on a year-over-year basis. Equities analysts predict that Keryx Biopharmaceuticals Inc. will post ($1.23) earnings per share for the current fiscal year.

In related news, CFO Scott A. Holmes sold 4,935 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

An institutional investor recently raised its position in Keryx Biopharmaceuticals stock. Schwab Charles Investment Management Inc. raised its stake in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) by 3.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 375,655 shares of the biopharmaceutical company’s stock after buying an additional 13,405 shares during the period. Schwab Charles Investment Management Inc. owned about 0.36% of Keryx Biopharmaceuticals worth $1,898,000 as of its most recent SEC filing.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.